United Therapeutics (NASDAQ:UTHR) Sets New 1-Year High at $275.42

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $275.42 and last traded at $275.16, with a volume of 139205 shares changing hands. The stock had previously closed at $274.26.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on UTHR shares. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They set an "outperform" rating and a $330.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. Oppenheimer increased their price target on United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research report on Thursday, May 2nd. Wells Fargo & Company increased their price target on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research report on Thursday, March 7th. Finally, Leerink Partnrs reissued an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $308.78.

United Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The company has a market cap of $12.18 billion, a P/E ratio of 12.99 and a beta of 0.54. The firm has a 50 day moving average price of $244.51 and a two-hundred day moving average price of $232.72.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analysts' expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm's quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.86 EPS. On average, analysts predict that United Therapeutics Co. will post 24.2 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Nilda Mesa sold 325 shares of the firm's stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the sale, the director now owns 5,373 shares of the company's stock, valued at approximately $1,277,699.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, Director Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $272.37, for a total value of $980,532.00. Following the sale, the director now owns 130 shares of the company's stock, valued at approximately $35,408.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 325 shares of the firm's stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the completion of the sale, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 153,740 shares of company stock valued at $37,031,694. Corporate insiders own 12.50% of the company's stock.

Institutional Trading of United Therapeutics

A number of hedge funds have recently bought and sold shares of UTHR. Rise Advisors LLC bought a new stake in United Therapeutics in the 1st quarter worth approximately $32,000. GAMMA Investing LLC bought a new stake in United Therapeutics in the fourth quarter valued at approximately $43,000. Benjamin F. Edwards & Company Inc. lifted its position in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 117 shares during the last quarter. C M Bidwell & Associates Ltd. bought a new stake in United Therapeutics in the third quarter valued at approximately $91,000. Finally, Janiczek Wealth Management LLC lifted its position in United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company's stock valued at $111,000 after purchasing an additional 84 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.